Company Overview - Emergent BioSolutions (EBS) stock gained nearly 12% on the day following an analyst's initiation of coverage, contrasting with the S&P 500's 1% decline [2] - H C Wainwright's Raghuram Selvaraju initiated coverage with a buy recommendation and a price target of $15 per share, which is 62% higher than the stock's current level [3] - The company is well positioned to be a frontline player in potential future healthcare emergencies due to its diversified offerings [4][6] Business Segments - The company's vaccines business includes jabs for monkeypox and smallpox, with monkeypox recently highlighted as a potential global healthcare threat [1] - Emergent's Narcan opioid reversal spray is expected to continue experiencing heavy demand due to the ongoing opioid epidemic in the U S [5] Analyst Perspective - Raghuram Selvaraju views Emergent as well diversified across several medical segments with strong growth potential [5] - The analyst's positive outlook on the company's diversification makes the stock a worthy consideration for investment [6]

Shares of Emergent BioSolutions (EBS) have more than doubled in market cap so far this year, outperforming the industry’s 13% decline, as seen in the chart below. This surge in stock price started earlier this year after management announced several strategic changes to enhance profitability and stabilize its financial position. During the same period, the stock has also outperformed the broader Medical sector and the S&P 500. It is currently trading above its 200-day moving average.EBS Stock Outperforms In ...

GAITHERSBURG, Md., Dec. 16, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) today announced that the Biomedical Advanced Research and Development Authority (BARDA) within the Administration for Strategic Preparedness and Response (ASPR) at the U.S. Department of Health and Human Services has awarded a $50 million option to Emergent's existing contract (HHSO100201600030C) for the acquisition of CYFENDUS® (Anthrax Vaccine Adsorbed, Adjuvanted). Deliveries are expected to begin this calendar yea ...

Emergent BioSolutions (EBS -5.59%) saw its shares tumble on Tuesday, due to news of a share sell-off. The vaccine maker divulged in a regulatory filing that several institutional share and warrant holders are selling such securities. Investors reacted by trading Emergent's stock down by almost 6%, on a day when the S&P 500 (^GSPC 0.05%) more or less flatlined.Unloading shares and exercising warrantsThe selling parties are mainly entities affiliated with OHA Agency, a business that provided a $250 million te ...

If you like what you have just read and want to receive at least 4 exclusive stock tips every week focused on Pharma, Biotech and Healthcare, then join me at my marketplace channel, Haggerston BioHealth . Invest alongside the model portfolio or simply access the investment bank-grade financial models and research. I hope to see you there.Emergent BioSolutions (NYSE: EBS ), the Gaithersburg, Maryland headquartered biotech reported its Q3 earnings on Wednesday 6th November, after the bell, leading to a 20% su ...

Core Viewpoint - Emergent BioSolutions Inc. reported mixed third-quarter earnings, with a notable increase in stock price driven by new mpox trials in Africa and a significant turnaround in adjusted EPS [1][5]. Financial Performance - Third-quarter sales reached $293.8 million, a 9% increase year over year, but fell short of the consensus estimate of $297.5 million [1]. - Adjusted EPS was $1.37, a recovery from a loss of $1.09 a year ago, exceeding the consensus of $0.14 [1]. Revenue Breakdown - Revenues from Narcan Nasal Spray decreased by 33% to $95.3 million due to the transition to over-the-counter sales and lower Canadian retail sales, although OTC Narcan sales increased [2]. - Anthrax MCM revenues fell by 65% to $11.4 million, while Smallpox MCM sales surged over fivefold to $132.7 million [2]. Guidance Updates - The company revised its 2024 revenue guidance to $1.065 billion – $1.125 billion, slightly below the previous range and consensus of $1.123 billion [3]. - Commercial product sales guidance was adjusted to $420 million – $430 million, down from $450 million – $480 million [3]. - MCM product sales outlook was updated to $510 million – $550 million, compared to the earlier expectation of $455 million – $490 million [3]. Services Segment and Loss Projections - Services segment sales are now expected to be $105 million – $110 million, lower than the previous range of $120 million – $130 million [4]. - The company anticipates a 2024 net loss of $203 million – $183 million, an improvement from the earlier loss range of $314 million – $274 million [4]. - Adjusted EBITDA is forecasted to be $180 million – $200 million, up from the previous forecast of $140 million – $180 million [4]. New Trials and Initiatives - Emergent BioSolutions announced a new trial for brincidofovir (Tembexa) to treat mpox, sponsored by PANTHER and led by the Africa Centres for Disease Control and Prevention, set to begin in the Democratic Republic of Congo [5]. Stock Performance - EBS stock increased by 28.3%, reaching $11.80 during the latest trading session [6].

Here are five stocks added to the Zacks Rank #1 (Strong Buy) List today:Moody's Corporation (MCO) : This integrated risk assessment firm has seen the Zacks Consensus Estimate for its current year earnings increasing 6.3% over the last 60 days.Emergent BioSolutions Inc. (EBS) : This life sciences company has seen the Zacks Consensus Estimate for its current year earnings increasing 34.3% over the last 60 days.LivaNova PLC (LIVN) : This medical device company has seen the Zacks Consensus Estimate for its curr ...

Financial Data and Key Metrics - Total revenues for Q3 2024 were $294 million, a 9% year-over-year improvement, at the upper end of the guidance range [19] - Adjusted EBITDA for Q3 2024 was $105 million, or 36% of revenues, an improvement of $85 million versus the prior year [19] - Year-to-date revenue was $849 million, up 10% versus the prior year, driven by U.S. government and international medical countermeasures [24] - Year-to-date adjusted EBITDA was $162 million, an improvement of $188 million versus the prior year [24] - Net debt was reduced to $551 million, a $206 million reduction since the beginning of 2024 [17] Business Line Performance - NARCAN sales were $95 million in Q3 2024, with year-to-date volumes up 7% [18][20] - Anthrax MCM sales were $11 million, a decrease versus the prior year due to timing of deliveries [21] - Smallpox MCM sales were $133 million, including deliveries of ACAM2000 and VIGIV contract options to the U.S. government [21] - Other product sales, including BAT, were $30 million, and Bioservices revenues were $14 million [21] Market Performance - NARCAN volumes increased year-to-date, driven by strong demand in the U.S. public interest channel and expanded categories like business and retail channels [11][31] - The company received FDA approval for ACAM2000 to include the mpox expanded indication, strengthening its smallpox portfolio [11][36] - The company secured over $500 million in medical countermeasure contract modifications for Anthrax MCM, Smallpox MCM, and BAT [18] Strategic Direction and Industry Competition - The company is transitioning from the stabilization phase to the turnaround phase of its multi-year plan, focusing on operational improvements and profitable growth [7][8] - The company is strategically focusing on international expansion and line extensions of current products, such as NARCAN, to drive future growth [39] - The company is leveraging its unique position in medical countermeasures to engage with U.S. and international governments, responding to public health threats like mpox and Ebola [35][37] Management Commentary on Operating Environment and Future Outlook - Management expressed confidence in the bipartisan support for the company's mission to combat public health threats like opioid overdoses and biodefense [13] - The company raised its 2024 revenue and adjusted EBITDA guidance, reflecting strong performance and improved financial stability [9][25] - Management highlighted the importance of maintaining competitive pricing for NARCAN while leveraging its brand and distribution capabilities to sustain market leadership [57][58] Other Important Information - The company successfully refinanced its debt, closing a $250 million term loan with Oak Hill Advisors and a $100 million asset-backed revolving credit facility with Wells Fargo [10][16] - The company resolved legacy compliance and legal matters, including a $50 million settlement with Janssen Pharmaceuticals [15] - The company appointed Dr. Simon Lowry as Head of R&D and Chief Medical Officer, and promoted Jessica Perl to General Counsel and Corporate Secretary [12] Q&A Session Summary Question: Long-term gross margin outlook for NARCAN - The company expects NARCAN gross margins to stabilize around the current level of 50%, with ongoing efforts to improve cost of goods sold [45] Question: New growth opportunities and asset acquisitions - The company is focused on both internal growth opportunities, such as NARCAN line extensions and geographic expansion, and external business development deals that align with its capabilities [47][51] Question: Factors impacting NARCAN guidance and competitive dynamics - NARCAN guidance was adjusted due to competitive pricing pressures and discontinued RX NARCAN sales, but volumes remain strong with 7% year-to-date growth [55][59] - Pricing in the NARCAN market has stabilized, with the majority of sales still coming from the public interest market [61][63] Question: Smallpox contract deliveries and future revenue recognition - A significant portion of the $400 million Smallpox contract will be recognized in 2025, with some revenue expected in Q4 2024 [65] Question: Asset sales and future site utilization - The company is evaluating further asset sales and site utilization, with a focus on reducing operating expenses while maintaining manufacturing capabilities [70][72] Question: Long-term EBITDA potential - The company has significantly reduced operating expenses and streamlined its site network, positioning itself for improved profitability, though specific 2025 guidance was not provided [74][75]

Emergent Biosolutions (EBS) came out with quarterly earnings of $1.37 per share, beating the Zacks Consensus Estimate of $0.49 per share. This compares to loss of $1.44 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 179.59%. A quarter ago, it was expected that this biopharmaceutical company would post a loss of $0.97 per share when it actually produced a loss of $2.32, delivering a surprise of -139.18%.Over the last four quar ...

| --- | --- | |----------------------------|-------| | | | | | | | | | | | | | Q3 2024 | | | Financial | | | Results | | | Update | | | November 6, 2024 | | | | | | | | | | | | Proprietary & Confidential | | PROPRIETARY AND CONFIDENTIAL Q3 2024 Update Introduction INTRODUCTION Safe Harbor Statement/Trademarks This presentation includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical fact, including sta ...